NCT07928388
Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: Through study completion, up to 4 years
Arms and interventions
Treatment ArmExperimental
Oral MC-1
Drugs: Pyridoxal 5'-Phosphate
Sites
5 sites in 2 countries
United States 3, Australia 2